Clinical Evidence and Translational Evaluation of an NVTIA Guarana Extract-EGCG-Konjac Glucomannan Composition for Weight Management in Adults with Overweight

Abstract

Background: We evaluated a three-component NVTIA composition that combines guarana extract, epigallocatechin gallate (EGCG), and konjac glucomannan for weight management. Instead of presenting non-verified simulated human outcomes, we retained the formulation data already available in the manuscript and matched them with published clinical trial evidence. Methods: We searched PubMed-indexed randomized trials, systematic reviews, meta-analyses, ClinicalTrials.gov records, NIH Office of Dietary Supplements materials, and EU regulatory texts through March 2026 for human studies involving guarana, Paullinia cupana, green tea catechins, EGCG, glucomannan, konjac, overweight, obesity, appetite, or weight loss. Results: The retained formulation dataset showed strong gastric protection and programmed release behavior, with EGCG retention of 83.9% to 88.7% after 2 h in simulated gastric fluid and cumulative colonic-phase release of 96.7% to 98.1% at 12 h [1]. The published human literature did not reveal a randomized trial of this exact three-component composition, but it did support a coherent component-level rationale. Green tea catechin systems generally produced modest effects, with pooled estimates around 1 kg of body-weight reduction and stronger abdominal-fat changes in some exercise-supported settings [2-5,16]. Glucomannan showed mixed but directionally favorable evidence, ranging from a null pooled estimate in an older meta-analysis to a small benefit in later syntheses [12-16]. Guarana-related evidence in weight management remained limited and was strongest in combination products or acute metabolic studies rather than in direct monotherapy obesity trials [9-11]. Conclusions: We conclude that the present composition has a clinically plausible translational basis, especially as an adjunct to energy restriction and physical activity, but the exact formula still requires a registered randomized trial before definitive efficacy claims can be made.